Javascript must be enabled to continue!
Effect of withaferin a on Ehrlich ascites tumor cells. II. Target tumor cell destruction in vivo by immune activation
View through CrossRef
AbstractIntraperitoneal administration of Withaferin A 24 h after inoculation of Ehrlich ascites carcinoma resulted in an immediate inhibition of tumor growth, followed by complete disappearance of the malignant cells after 3‐4 days. During this period a striking proliferation of macrophages in the peritoneal cavity and clustering of viable acid‐phosphatase‐rich macrophages around Ehrlich ascites tumor cells was observed. In addition, giant cell formation in the peritoneal cavity of the tumor‐rejecting mice was commonly seen. No significant difference was found in the number of lymphocytes and polymorphonuclears of the peritoneal exudate of the tumor‐rejecting mice as compared to untreated tumor‐bearing mice. A similar sequence of changes with an even more striking proliferation of macrophages terminating again in complete tumor regression was observed after reinoculation of Ehrlich ascites cells to Withaferin A cured mice. Growth of Ehrlich ascites tumor cells in normal mice was prevented by passive transfer of serum or peritoneal cells, but not by spleen cells taken from immune mice. Humoral antibodies in the serum of immune mice were demonstrated by the complement fixation, the passive cutaneous anaphylaxis, and the cytotoxic tests. One‐day‐old suckling litters born to immune mothers were also refractory to Ehrlich ascites implantation. However, Ehrlich ascites cell growth was not affected if the litters were injected previously with a cell‐free tumor homogenate.
Title: Effect of withaferin a on Ehrlich ascites tumor cells. II. Target tumor cell destruction in vivo by immune activation
Description:
AbstractIntraperitoneal administration of Withaferin A 24 h after inoculation of Ehrlich ascites carcinoma resulted in an immediate inhibition of tumor growth, followed by complete disappearance of the malignant cells after 3‐4 days.
During this period a striking proliferation of macrophages in the peritoneal cavity and clustering of viable acid‐phosphatase‐rich macrophages around Ehrlich ascites tumor cells was observed.
In addition, giant cell formation in the peritoneal cavity of the tumor‐rejecting mice was commonly seen.
No significant difference was found in the number of lymphocytes and polymorphonuclears of the peritoneal exudate of the tumor‐rejecting mice as compared to untreated tumor‐bearing mice.
A similar sequence of changes with an even more striking proliferation of macrophages terminating again in complete tumor regression was observed after reinoculation of Ehrlich ascites cells to Withaferin A cured mice.
Growth of Ehrlich ascites tumor cells in normal mice was prevented by passive transfer of serum or peritoneal cells, but not by spleen cells taken from immune mice.
Humoral antibodies in the serum of immune mice were demonstrated by the complement fixation, the passive cutaneous anaphylaxis, and the cytotoxic tests.
One‐day‐old suckling litters born to immune mothers were also refractory to Ehrlich ascites implantation.
However, Ehrlich ascites cell growth was not affected if the litters were injected previously with a cell‐free tumor homogenate.
Related Results
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...
Abstract B140: Autologous human growing tumor model and its immunological relevance for cancer immunology research
Abstract B140: Autologous human growing tumor model and its immunological relevance for cancer immunology research
Abstract
Background: Tumors grow in accordance with immunoediting. If we can see the changes of immune characteristics in the microenvironment during tumor growth, w...
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...
Abstract 1798: ALDH inhibition as modulator of ovarian tumor associated immune cells
Abstract 1798: ALDH inhibition as modulator of ovarian tumor associated immune cells
Abstract
Rationale: Ovarian cancer (OC) is an aggressive disease with the 3rd highest mortality to incidence ratio of all cancers. Aldehyde dehydrogenase-1A enzymes ...
Eugen Ehrlich: Bibliographic Index [E-book, PDF]
Eugen Ehrlich: Bibliographic Index [E-book, PDF]
The Bibliographic Index EUGEN EHRLICH is a guide through available materials containing information about the life, scientific, educational, legislative and social activities of th...
Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
Background: CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved high response rates in patients with B-cell lymphoma (BCL). However, treatment failure and relapse can ...
Abstract P4-01-29: Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2- metastatic breast cancer
Abstract P4-01-29: Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2- metastatic breast cancer
Abstract
Background The combination of CDK4/6 inhibitors and endocrine therapy is the current standard first-line therapy for patients with HR+/HER2- metastatic brea...


